Latest & greatest articles for prednisone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prednisone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prednisone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prednisone

61. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma

Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment (...) of elderly patients with diffuse large B-cell lymphoma Hornberger J C, Best J H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) was compared with rituximab plus

NHS Economic Evaluation Database.2005

62. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. 15470213 2004 10 07 2004 10 12 2016 08 03 1533-4406 351 15 2004 Oct 07 The New England journal of medicine N. Engl. J. Med. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. 1502-12 Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prostate cancer, but it does not improve survival. We compared (...) such treatment with docetaxel plus prednisone in men with this disease. From March 2000 through June 2002, 1006 men with metastatic hormone-refractory prostate cancer received 5 mg of prednisone twice daily and were randomly assigned to receive 12 mg of mitoxantrone per square meter of body-surface area every three weeks, 75 mg of docetaxel per square meter every three weeks, or 30 mg of docetaxel per square meter weekly for five of every six weeks. The primary end point was overall survival. Secondary end

NEJM2004

63. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. 15470214 2004 10 07 2004 10 12 2016 08 03 1533-4406 351 15 2004 Oct 07 The New England journal of medicine N. Engl. J. Med. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. 1513-20 Mitoxantrone-based chemotherapy palliates pain without extending survival in men with progressive androgen-independent prostate cancer. We compared (...) docetaxel plus estramustine with mitoxantrone plus prednisone in men with metastatic, hormone-independent prostate cancer. We randomly assigned 770 men to one of two treatments, each given in 21-day cycles: 280 mg of estramustine three times daily on days 1 through 5, 60 mg of docetaxel per square meter of body-surface area on day 2, and 60 mg of dexamethasone in three divided doses before docetaxel, or 12 mg of mitoxantrone per square meter on day 1 plus 5 mg of prednisone twice daily. The primary end

NEJM2004

64. Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma

Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma Kouroukis C T, O'Brien B J, Benger A, Marcellus D, Foley R, Garner J, Ingram C, Haines P, Henderson-O'Connor N (...) costs appear to have been reported. The resource quantities were reported separately from the costs. The direct costs included at analysis appear to have been those of the health service. These included chemotherapy costs, other supportive medication (G-CSF and pamidronate), chemotherapy administration, total body irradiation, stem cell costs, in-hospital costs and other costs. The chemotherapy costs were for prednisone, dexamethasone, melphalan, vincristine, doxorubicin and cyclophosphamine

NHS Economic Evaluation Database.2003

65. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease.

Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. 12826636 2003 06 26 2003 07 08 2014 11 20 1533-4406 348 26 2003 Jun 26 The New England journal of medicine N. Engl. J. Med. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. 2618-25 In this randomized, double-blind, placebo-controlled trial, we studied the effectiveness of prednisone in reducing the risk of relapse after outpatient exacerbations (...) of chronic obstructive pulmonary disease (COPD). We enrolled 147 patients who were being discharged from the emergency department after an exacerbation of COPD and randomly assigned them to 10 days of treatment with 40 mg of oral prednisone once daily or identical-appearing placebo. All patients received oral antibiotics for 10 days, plus inhaled bronchodilators. The primary end point was relapse, defined as an unscheduled visit to a physician's office or a return to the emergency department because of worsening dyspnea, within 30

NEJM2003

66. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial.

Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. 11809183 2002 01 25 2002 02 13 2015 06 16 0140-6736 359 9300 2002 Jan 05 Lancet (London, England) Lancet Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. 23 (...) . 122 adults with severe AITP (platelet count < or =20 x 10(9)/L) were randomly assigned to receive either intravenous immunoglobulin or high-dose methylprednisolone on days 1-3 (randomisation A), and then to receive either oral prednisone or placebo (randomisation B) on days 4-21. Analysis was by intention to treat. Six patients were excluded from the analysis. The number of days on which platelet counts were above 50 x 10(9)/L was 18 in 56 patients receiving intravenous immunoglobulin and 14 in 60

Lancet2002

67. Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma

Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years (...) relative to other cost-utility ratios of other health care interventions. Source of funding Supported by research grants from the Norwegian Cancer Society. Bibliographic details Gulbrandsen N, Wisloff F, Nord E, Lenhoff S, Hjorth M, Westin J. Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma. European Journal of Haematology 2001; 66(5): 328-336 PubMedID Other publications of related

NHS Economic Evaluation Database.2001

68. Comparative efficacy of oral dexamethasone versus oral prednisone in acute pediatric asthma

Comparative efficacy of oral dexamethasone versus oral prednisone in acute pediatric asthma PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2001

69. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma.

A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2000

70. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma.

A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. 10974132 2000 09 07 2000 09 07 2015 11 19 0028-4793 343 10 2000 Sep 07 The New England journal of medicine N. Engl. J. Med. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. 689-94 Inhaled corticosteroids are effective in the treatment of children with asthma. It is uncertain how inhaled corticosteroids compare with oral corticosteroids in the management (...) of severe acute disease. We performed a double-blind, randomized trial involving 100 children five years of age or older who had severe acute asthma (indicated by a forced expiratory volume in one second [FEV1] that was less than 60 percent of the predicted value) and in whom the results could be evaluated. All were treated with an aggressive bronchodilator regimen and received one dose of either 2 mg of inhaled fluticasone through a metered-dose inhaler with a spacer or 2 mg of oral prednisone per

NEJM2000

71. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis.

Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. 10727589 2000 03 23 2000 03 23 2013 11 21 0028-4793 342 12 2000 Mar 23 The New England journal of medicine N. Engl. J. Med. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. 851-9 It is uncertain whether the growth impairment that occurs in children during long-term treatment with glucocorticoids persists after (...) the medication is discontinued and ultimately affects adult height. We evaluated growth six to seven years after alternate-day treatment with prednisone had been discontinued in 224 children 6 to 14 years of age with cystic fibrosis who had participated in a multicenter trial of this therapy from 1986 through 1991. Of the children, 151 had been randomly assigned to receive prednisone (either 1 or 2 mg per kilogram of body weight) and 73 to receive placebo. We obtained data on growth up to 1997 from

NEJM2000

72. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points

Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based (...) mitoxantrone and prednisone (M+P) was compared to prednisone alone (P) in patients with symptomatic hormone-resistant prostate cancer (HRPC). Type of intervention Palliative care. Economic study type Cost-utility analysis. Study population The study population comprised patients with symptomatic HRPC and pain. No further inclusion or exclusion criteria were reported. Setting The setting was tertiary care. The economic study was carried out in Canada. Dates to which data relate The dates during which

NHS Economic Evaluation Database.1998

73. Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha2b in newly diagnosed multiple myeloma: results from a randomised controlled trial

Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha2b in newly diagnosed multiple myeloma: results from a randomised controlled trial Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha2b in newly diagnosed multiple myeloma: results from a randomised controlled trial Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha2b in newly diagnosed multiple myeloma: results from a randomised controlled trial (...) Nord E, Wisloff F, Hjorth M, Westin J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Melphalan plus prednisone with interferon-Alpha2b (MP-IFN) in patients with newly-diagnosed multiple myeloma. Type of intervention Treatment

NHS Economic Evaluation Database.1997

74. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.

A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. 9110907 1997 04 24 1997 04 24 2013 11 21 0028-4793 336 17 1997 Apr 24 The New England journal of medicine N. Engl. J. Med. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. 1202-7 Primary systemic amyloidosis is an uncommon disease characterized by the accumulation (...) in vital organs of a fibrillar protein consisting of monoclonal light chains. We treated 220 patients with biopsy-proved amyloidosis. The patients were randomly assigned to receive colchicine (72 patients), melphalan and prednisone (77), or melphalan, prednisone, and colchicine (71). They were stratified according to their chief clinical manifestations: renal disease (105 patients), cardiac involvement (46), peripheral neuropathy (19), or other (50). The median duration of survival after randomization

NEJM1997

75. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss.

Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. 9219700 1997 07 17 1997 07 17 2013 11 21 0028-4793 337 3 1997 Jul 17 The New England journal of medicine N. Engl. J. Med. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. 148-53 Recurrent fetal loss has been well described in women with antiphospholipid antibodies. Such women also often have other autoantibodies commonly found in patients (...) with systemic lupus erythematosus. Treating them with prednisone and aspirin may reduce the risk of fetal loss. We screened 773 nonpregnant women who had the unexplained loss of at least two fetuses for antinuclear, anti-DNA, antilymphocyte, and anticardiolipin antibodies and for the lupus anticoagulant. Of 385 women with at least one autoantibody, 202 who later became pregnant were randomly assigned in equal numbers to receive either prednisone (0.5 to 0.8 mg per kilogram of body weight per day) and aspirin (100 mg per day

NEJM1997

76. Randomized, prospective trial of cyclosporine monotherapy versus azathioprine-prednisone from three months after renal transplantation

Randomized, prospective trial of cyclosporine monotherapy versus azathioprine-prednisone from three months after renal transplantation Randomized, prospective trial of cyclosporine monotherapy versus azathioprine-prednisone from three months after renal transplantation Randomized, prospective trial of cyclosporine monotherapy versus azathioprine-prednisone from three months after renal transplantation Hilbrands L B, Hoitsma A J, Koene K A Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Using cyclosporine monotherapy (CsA) or a combination of azathioprine (Aza) and prednisone (Pred) in patients receiving CsA and Pred during the first 3 months after renal transplantation. Type of intervention Secondary prevention and treatment

NHS Economic Evaluation Database.1996

77. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. 8676625 1996 08 15 1996 08 15 2015 06 16 0140-6736 347 9013 1996 May 25 Lancet (London, England) Lancet Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia (...) . The French Cooperative Group on CLL. 1432-8 Fludarabine seems to be a promising treatment for patients with advanced chronic lymphocytic leukaemia (CLL). We compared fludarabine therapy with the combination of cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of CLL in a randomised, multicentre prospective trial. Patients older than 18 years of age were entered into the study if they presented with previously untreated B-cell lineage CLL (B-CLL) of Binet stages B or C or relapsed B-CLL

Lancet1996

78. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura.

Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. 7915773 1994 10 05 1994 10 05 2015 11 19 0140-6736 344 8924 1994 Sep 10 Lancet (London, England) Lancet Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. 703-7 The most serious complication of childhood acute immune thrombocytopenic purpura (ITP), intracranial (...) prednisone 4 mg/kg per day with tapering and discontinuation of prednisone by day 21 (n = 39). The rate of response as reflected by the number of days with platelet counts at 20 x 10(9)/L or lower and the time taken to achieve a platelet count 50 x 10(9)/L or more was significantly faster for both IVIgG groups than for the anti-D group (p < 0.05); the difference between prednisone and IVIgG was significant (p < 0.05) only for the IVIgG 0.8 g/kg group, and responses to the two IgG groups were similar

Lancet1994

79. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy.

Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. 8105213 1993 11 10 1993 11 10 2015 06 16 0140-6736 342 8877 1993 Oct 16 Lancet (London, England) Lancet Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. 949-54 Corticosteroids are usually given for management of Graves' ophthalmopathy, but they have many and serious side-effects. By comparison, retrobulbar irradiation is well tolerated, although its efficacy has (...) been evaluated only in uncontrolled studies. Therefore, we did a double-blind randomised trial, in which 28 patients with moderately severe Graves' ophthalmopathy were treated with a 3-month course of oral prednisone and sham irradiation, and 28 received retrobulbar irradiation (20 Gy) and placebo capsules. Therapeutic outcome, assessed twenty-four weeks after the start of treatment, was determined by the change in the highest NOSPECS class. A successful outcome was observed in 14 prednisone

Lancet1993

80. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.

Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. 8413388 1993 10 26 1993 10 26 2013 11 21 0028-4793 329 17 1993 Oct 21 The New England journal of medicine N. Engl. J. Med. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. 1225-30 Acute graft-versus-host disease (GVHD) following allogeneic bone marrow transplantation (...) remains a serious problem. In a clinical trial, we tested the combination of cyclosporine and prednisone with and without methotrexate for the prevention of GVHD. One hundred fifty patients with either acute leukemia in first complete remission, chronic myelogenous leukemia in first chronic phase, or lymphoblastic lymphoma in first complete remission were enrolled in the study. All the patients were given fractionated total-body irradiation (1320 cGy) and etoposide (60 mg per kilogram of body weight

NEJM1993